PRODUCT INFORMATION
EFICUR 50 mg/ml Ceftiocur 50mg/ml
BENEFITS • • • • •
Excellent syringeability allowing product to be injected quicker, saving time and stress Shortest withdrawal period of any cephalosporin- milk 0 days and meat 2 days User friendly with subcutaneous administration route 250ml plastic bottle for better protection and less breakages Total bioavailability resulting in 100% of the antibiotic active for the volume administered
PACKAGING LIST NO. 1EFI001
UNIT PACKAGE 100ml
CASE SIZE 100
See reverse side for full indications, administration and dosage.
Bimeda® a division of the Cross Vetpharm Group Ltd. Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie
TECHNICAL PRODUCT INFORMATION INFORMATION
EFICUR 50 mg/ml suspension Presentation A white or yellowish oily suspension for injection in cattle and swine. 1ml contains Ceftiofur 50 mg (as Ceftiofur Hydrochloride) Target Species Swine and cattle. Use Infections associated with bacteria sensitive to ceftiofur: Swine: - Treatment of bacterial respiratory disease associated with Pasteurella multocida, Actinobacillus pleuropneumoniae and Streptococcus suis. Cattle: - For the treatment of bacterial respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida and Haemophilus somnus. - For the treatment of acute interdigital necrobacillosis (panaritium, foot rot) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus (Phorphyromonas asaccharolytica). - For the treatment of the bacterial component of acute post-partum (puerperal) metritis within 10 days after calving associated with Escherichia coli, Arcanobacterium pyogenes and Fusobacterium necrophorum. Contra-indications, Warnings, etc. Do not administer to an animal previously found to be hypersensitive to ceftiofur and other _-lactam antibiotics. Do not inject intravenously Special precautions for use i) Special precautions for use in animals Shake the bottle well before use to bring the product back into suspension. In case of the occurrence of allergic reaction the treatment should be withdrawn. Inappropriate use of the product may increase the prevalence of bacteria resistant to cephalosporins. Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies ii) Special precaution to be taken by the person administering the medicinal product to animals Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious. People with known hypersensitivity to penicillins or cephalosporins should avoid contact with the product. In the case of accidental self-injection or following exposure, if you develop symptoms such as a skin rash, seek medical advice immediately and show the package leaflet or the label to the physician. Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention. Adverse reactions (frequency and seriousness) Hypersensitivity reactions unrelated to dose can occur. Allergic reactions
(e.g. skin reactions, anaphylaxia) may occasionally occur. In swine, mild reactions at the injection site, such as discoloration of the fascia or fat, have been observed in some animals for up to 20 days after injection. In cattle, mild inflammatory reactions at the injection site, such as tissue oedema and discoloration of the subcutaneous tissue and/or fascial surface of the muscle may be observed. Clinical resolution is reached in most animals by 10 days after injection although slight tissue discoloration may persist for 28 days or more. Use during pregnancy, lactation or lay Studies in laboratory species have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Safety has not been established in the target species during pregnancy. Use only according to the benefit/risk assessment by the responsible veterinarian. Amounts to be administered and administration route Swine: 3 mg ceftiofur/kg bw/day for 3 days by intramuscular injection, i.e. 1 ml of the product /16 kg bw/day. Cattle: Treatment of respiratory disease: 1 mg ceftiofur/kg bw/day for 3 to 5 days by subcutaneous injection, i.e. 1 ml of the product /50kg bw/day. Treatment of acute interdigital necrobacillosis: 1 mg ceftiofur/kg bw/day for 3 days by subcutaneous injection, i.e. 1 ml of the product/50 kg bw/day. Acute post-partum metritis within 10 days after calving: 1 mg ceftiofur/kg bw/ day for 5 consecutive days by subcutaneous injection, i.e. 1 ml of the product /50 kg bw/day. Subsequent injections must be given at different sites. In case of acute post-partum metritis, additional supportive therapy might be required in some cases. Shake well before use Overdose (symptoms, emergency procedures, antidotes), if necessary The low toxicity of ceftiofur has been demonstrated in swine using ceftiofur sodium at doses in excess of 8 times the recommended daily dose of ceftiofur intramuscularly administered for 15 consecutive days. In cattle, no signs of systemic toxicity have been observed following substantial parenteral overdosages. Withdrawal Period(s) Swine: - Meat and offal: 5 days. Cattle: - Meat and offal: 8 days List of excipients Aluminium monostearate Sorbitan oleate Triglycerides, medium-chain products. Shelf-life Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after first opening the immediate packaging: 28 days Special precautions for storage Do not store above 25 ÂşC Do not refrigerate or freeze VPA
10846/006/001
BimedaÂŽ a division of the Cross Vetpharm Group Ltd. Broomhill Road I Tallaght I Dublin 24 I Ireland Tel: 1850-515253 Fax: 01 451 5803 Web: www.bimeda.ie